BMRN vs. ROIV: BioMarin Pharmaceutical vs. Roivant Sciences Stock Comparison
How do BioMarin Pharmaceutical (BMRN) and Roivant Sciences (ROIV) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
BioMarin Pharmaceutical (BMRN) and Roivant Sciences (ROIV) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.
BioMarin Pharmaceutical (BMRN) has more than two decades of public-market history since July 26, 1999, whereas Roivant Sciences (ROIV) listed on December 8, 2020 and has a much shorter record to draw on.
| Profile Item | BMRN | ROIV |
|---|---|---|
| Name | BioMarin Pharmaceutical Inc. | Roivant Sciences Ltd. |
| Country/Region | United States | United Kingdom |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Biotechnology |
| GICS Sub-Industry | Biotechnology | Biotechnology |
| Market Capitalization | 10.85 billion USD | 28.08 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | July 26, 1999 | December 8, 2020 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | BMRN | ROIV |
|---|---|---|
| Total Return (1Y) | 8.82% | 96.75% |
| Total Return (3Y, Annualized) | -12.54% | 68.04% |
| Total Return (5Y, Annualized) | -7.51% | 36.73% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | BMRN | ROIV |
|---|---|---|
| Volatility (1Y, Annualized) | 35.50% | 47.99% |
| Beta (5Y) | 0.24 | 1.17 |
| Max Drawdown (5Y) | -57.64% | -79.22% |
| Avg. Volume (3M) | 2.28M | 7.82M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | BMRN | ROIV |
|---|---|---|
| Sharpe Ratio (1Y) | 0.13 | 1.93 |
| Sortino Ratio (1Y) | 0.23 | 4.03 |
Profitability
ROE (TTM)
Both BioMarin Pharmaceutical (BMRN) at -0.31% and Roivant Sciences (ROIV) at -8.52% report negative ROE values. Negative ROE can reflect losses or negative shareholders’ equity, so both readings need extra context.
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
-0.31%
- Max
- 109.18%
- Q3
- 6.23%
- BMRN
- -0.31%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
ROIV
Pharmaceuticals, Biotechnology & Life Sciences industry group
-8.52%
- Max
- 109.18%
- Q3
- 6.23%
- ROIV
- -8.52%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
BioMarin Pharmaceutical (BMRN) reports a negative net margin of -0.52%, usually indicating a net loss over the period. Meanwhile Roivant Sciences (ROIV) reports 0.00%, ranking against industry peers normally.
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
-0.52%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- BMRN
- -0.52%
- Q1
- -4.14%
- Min
- -17.05%
ROIV
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- Max
- 18.05%
- Q3
- 4.78%
- ROIV
- 0.00%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Roivant Sciences (ROIV) reports a negative operating margin of -25,408.11%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile BioMarin Pharmaceutical (BMRN) reports 26.58%, ranking against industry peers normally.
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
26.58%
- Max
- 83.12%
- BMRN
- 26.58%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
ROIV
Pharmaceuticals, Biotechnology & Life Sciences industry group
-25,408.11%
- Max
- 83.12%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
- ROIV
- -25,408.11%
Profitability Metrics
| Metric | BMRN | ROIV |
|---|---|---|
| ROE (TTM) | -0.31% | -8.52% |
| ROA (TTM) | 3.89% | -16.28% |
| Net Margin (TTM) | -0.52% | 0.00% |
| Operating Margin (TTM) | 26.58% | -25,408.11% |
| Gross Margin (TTM) | 53.21% | 0.00% |
Growth
Revenue Growth
BioMarin Pharmaceutical (BMRN) at 12.87% is around its peer norm for revenue growth, while Roivant Sciences (ROIV) at -71.57% drops into the bottom quartile, signaling weaker demand or pricing momentum.
EPS Growth
Only one side can be read here: BioMarin Pharmaceutical (BMRN) reports EPS growth of -18.55%, ranked against its industry; Roivant Sciences (ROIV) has no EPS growth figure this period.
Growth Metrics
| Metric | BMRN | ROIV |
|---|---|---|
| Revenue Growth (YoY) | 12.87% | -71.57% |
| Revenue Growth (3Y CAGR) | 15.40% | -36.01% |
| EPS Growth (YoY) | -18.55% | -- |
| EPS Growth (3Y CAGR) | 33.89% | -- |
Financial Strength
Current Ratio (MRQ)
Roivant Sciences (ROIV) at 16.72 carries current ratio above its industry’s typical mid-range, while BioMarin Pharmaceutical (BMRN) at 2.44 runs in the tighter-liquidity quartile — different working-capital profiles, both worth examining.
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.44
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- BMRN
- 2.44
- Min
- 0.10
ROIV
Pharmaceuticals, Biotechnology & Life Sciences industry group
16.72
- Max
- 25.13
- ROIV
- 16.72
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Roivant Sciences (ROIV) at 0.02 carries an industry-typical debt-to-equity mix, while BioMarin Pharmaceutical (BMRN) at 0.67 uses more debt funding than most peers.
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.67
- Max
- 1.42
- BMRN
- 0.67
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
ROIV
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.02
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- ROIV
- 0.02
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | BMRN | ROIV |
|---|---|---|
| Current Ratio (MRQ) | 2.44 | 16.72 |
| Debt / Equity (MRQ) | 0.67 | 0.02 |
| Net Debt / EBITDA | 4.04 | -- |
Dividends
Dividend Yield (TTM)
Neither BioMarin Pharmaceutical (BMRN) nor Roivant Sciences (ROIV) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BMRN
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ROIV
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ROIV
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither BioMarin Pharmaceutical (BMRN) nor Roivant Sciences (ROIV) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BMRN
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ROIV
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ROIV
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | BMRN | ROIV |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
Neither BioMarin Pharmaceutical (BMRN) nor Roivant Sciences (ROIV) reports a P/E ratio value for this period, so a direct comparison isn’t possible.
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- BMRN
- --
ROIV
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- ROIV
- --
P/S Ratio (TTM)
BioMarin Pharmaceutical (BMRN) at 2.97 sits in the cheaper P/S ratio quartile while Roivant Sciences (ROIV) at 3,728.61 prices above its industry range — a wide gap in sales valuation between them.
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.97
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- BMRN
- 2.97
- Min
- 0.01
ROIV
Pharmaceuticals, Biotechnology & Life Sciences industry group
3,728.61
- ROIV
- 3,728.61
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
BioMarin Pharmaceutical (BMRN) at 1.73 is valued about in line with its industry on P/B ratio, while Roivant Sciences (ROIV) at 6.64 carries an above-peer premium to book — ROIV is pricier on assets.
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.73
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- BMRN
- 1.73
- Q1
- 1.69
- Min
- -5.59
ROIV
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.64
- Max
- 13.53
- ROIV
- 6.64
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | BMRN | ROIV |
|---|---|---|
| P/E Ratio (TTM) | -- | -- |
| P/S Ratio (TTM) | 2.97 | 3,728.61 |
| P/B Ratio (MRQ) | 1.73 | 6.64 |
| Free Cash Flow Yield (TTM) | -0.15% | -3.98% |